Synopsis

Source of validity: Scientific
Rating (out of 5): 3

AMP-activated protein kinase (AMPK) is a cellular energy sensor that plays a key role in regulating metabolism, including in bone tissue. In recent years, scientific interest has grown in the potential of AMPK activation as a therapeutic strategy for osteoporosis. Preclinical studies have shown that AMPK activation can promote osteoblast differentiation (the cells responsible for bone formation) and inhibit osteoclastogenesis (the process by which bone is broken down). For example, pharmacological activators of AMPK, such as metformin and AICAR, have demonstrated the ability to increase bone mass and improve bone microarchitecture in animal models of osteoporosis. These effects are believed to result from AMPK's modulation of signaling pathways involved in bone metabolism, including the inhibition of RANKL-induced osteoclast formation and stimulation of the Runx2 pathway for osteoblast activity.

However, while the preclinical evidence is promising, direct clinical evidence in humans remains limited. There are ongoing and some completed observational studies suggesting that AMPK-activating drugs may reduce fracture risk, especially in diabetic patients taking metformin. Nevertheless, large-scale, randomized controlled trials specifically targeting osteoporosis with AMPK activators are lacking. Thus, while there is a scientific basis and growing experimental support for AMPK as a target in osteoporosis treatment, the evidence is not yet robust enough to warrant routine clinical use. Continued research may further clarify AMPK’s therapeutic potential in osteoporosis.

More about AMP-activated protein kinase (AMPK)
More about Osteoporosis

Other ingredients used for Osteoporosis

Other health conditions supported by AMP-activated protein kinase (AMPK)

Products containing AMP-activated protein kinase (AMPK)